Absorption, Distribution and Excretion
Propylene acetate is rapidly absorbed in male animals, with at least 75% absorbed within 168 hours (based on radiolabeled samples recovered from urine, tissues, cage cleaning fluid, and residual carcass). Female animals show even higher oral absorption (≥92%). Excretion is also rapid, primarily via urine. After 168 hours, the total excretion rate in females (92-96%) is higher than in males (66-85%). The drug is widely distributed, with the highest concentrations in fat, muscle, liver, blood, and kidneys. Residual levels are higher in males than in females. The drug may accumulate in adipose tissue. Clearance from the ovaries, pancreas, thymus, and thyroid gland is slower.

---

Metabolism / Metabolites
In animals, it hydrolyzes to form the corresponding acid, which is excreted in urine and feces. In plants, it rapidly degrades into the main metabolite—acid derivatives. In a rat metabolism study, two 14C-labeled propynyl derivatives of chlorpyrifos (one labeled on the 2-carbon of the pyridine ring, and the other uniformly labeled on the benzene ring, with a purity >98%) were administered by gavage to approximately 7-week-old male Tif:RAI f (SPF) rats at concentrations of 25.2 mg/kg ([2-14C]pyridyl) and 24.6 mg/kg ([U-14C]benzene ring), respectively. In urine, the main metabolite was identified as (R)-2-[4-(5-chloro-3-fluoro-2-pyridinoxy)-phenoxy]-propionic acid, reference material CGA-193469, representing 36.7% to 39.1% of the administered dose (AD). Metabolite component U3 was hydrolyzed upon treatment with NaOH or HCl to generate component U7 (i.e., CGA-193469). No altered propargyl was detected. In feces, the major metabolite (component F*7) corresponded to the urinary metabolite U7 (CGA 193469), accounting for 15.7% to 16.9% of AD. Metabolite component F*8 was identified as altered propargyl, accounting for 0.4% to 1.7% of AD. It has been reported that all metabolites in adipose tissue are acylglycerols, the majority of which are mixed diacylglycerols and triacylglycerols (approximately 3.5% and 17.0% of total metabolites, respectively). Prolynyl clonidine was extensively metabolized (residual proplynyl clonidine was less than 0.3%). The major metabolite in excrement was clonidine (CGA 193469) and its taurine conjugate. The metabolites in adipose tissue are diacylglycerols and triacylglycerols of clonidine.

Non-Human Toxicity Values
Rat dermal LD50 >2000 mg/kg
Rat inhalation LC50 2.325 mg/L air/4 hours
Male rat oral LD50 1392 mg/kg /clodenafil propyne technical grade/
Female rat oral LD50 2271 mg/kg /clodenafil propyne technical grade/
For more complete non-human toxicity data for clodenafil propyne (8 types in total), please visit the HSDB record page.

---

Toxicity Data
LC50 (rat) > 2,325 mg/m3/4h

[1]. Wenbi Guan, et al. Dissipation of clodinafop-propargyl and its metabolite in wheat field ecosystem. Bull Environ Contam Toxicol. 2013 Jun;90(6):750-5.

Clodinafop-propargyl is a carboxylic acid ester formed by the condensation of the carboxyl group of clodinafop with the hydroxyl group of propargyl-1-ol. It is widely used as a herbicide to control annual grass weeds in cereal crops. It has multiple functions, including as an EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor, herbicide, and agrochemical. It is a carboxylic acid ester, aromatic ether, organochlorine compound, organofluorine compound, pyridine compound, and propionamide compound. Its function is similar to that of propargyl-1-ol and clodinafop. Clodinafop-propargyl is used as a wheat herbicide. See also: clodinafop (note moved here).

C17H13CLFNO4

349.74

349.051

105512-06-9

Clodinafop-propargyl-13C6

92431

Off-white to yellow solid powder

1.3±0.1 g/cm3

432.7±45.0 °C at 760 mmHg

59.5 °C ; MP: 48.2-57.1 °C /Technical/

215.5±28.7 °C

0.0±1.0 mmHg at 25°C

1.559

2.33

0

6

7

24

461

1

ClC1C([H])=NC(=C(C=1[H])F)OC1C([H])=C([H])C(=C([H])C=1[H])O[C@@]([H])(C(=O)OC([H])([H])C#C[H])C([H])([H])[H]

JBDHZKLJNAIJNC-LLVKDONJSA-N

InChI=1S/C17H13ClFNO4/c1-3-8-22-17(21)11(2)23-13-4-6-14(7-5-13)24-16-15(19)9-12(18)10-20-16/h1,4-7,9-11H,8H2,2H3/t11-/m1/s1

prop-2-ynyl (2R)-2-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenoxy]propanoate

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO: 100 mg/mL (285.93 mM)

Solubility in Formulation 1: 2.5 mg/mL (7.15 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)